Seasonal changes in prescribing of long-acting beta-2-agonists-containing drugs

Autor: Rottenkolber, M., Voogd, E., van Dijk, L., Primatesta, P., Becker, C., de Groot, M.C.H., Plana, E., Alvarez, Y., Durand, J., Slattery, J., Afonso, A., Requena, G., Huerta, C., Alvarez, A., de Abajo, F., Tauscher, M., Hasford, J., Fischer, R., Reynolds, R., Schmiedl, S.

Publikováno v: In Respiratory Medicine July 2015 109(7):828-837

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Oral insulin therapy for primary prevention of type 1 diabetes in infants with high genetic risk: the GPPAD-POInT (global platform for the prevention of autoimmune diabetes primary oral insulin trial) study protocol

Autor: Ziegler, A, Achenbach, P, Berner, R, Casteels, K, Danne, T, Gündert, M, Hasford, J, Hoffmann, V, Kordonouri, O, Lange, K, Elding Larsson, H, Lundgren, M, Snape, M, Szypowska, A, Todd, J, Bonifacio, E, Group, Gppad Study

Publikováno v: BMJ Open
BMJ Open 9:e028578 (2019)

IntroductionThe POInT study, an investigator initiated, randomised, placebo-controlled, double-blind, multicentre primary prevention trial is conducted to determine whether daily administration of oral insulin, from age 4.0 months to 7.0 months until

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79ccb2a2d1c75336a8a4eb03e1710419
http://europepmc.org/articles/PMC6609035

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

Autor: Hehlmann, R., Lauseker, M., Baerlocher, G. M., Heim, D., Brümmendorf, T. H., Fabarius, A., Haferlach, C., Schlegelberger, B., Müller, M. C., Jeromin, S., Proetel, U., Kohlbrenner, K., Saußele, S., Voskanyan, A., Rinaldetti, S., Seifarth, W., Spieß, B., Balleisen, L., Goebeler, M. C., Hänel, M., Ho, A., Dengler, J., Falge, C., Pfirrmann, M., Kanz, L., Kremers, S., Burchert, A., Kneba, M., Stegelmann, F., Köhne, C. A., Lindemann, H. W., Waller, C. F., Pfreundschuh, M., Spiekermann, K., Krause, S., Berdel, W. E., Müller, L., Edinger, M., Mayer, J., Beelen, D. W., Bentz, M., Link, H., Hertenstein, B., Fuchs, Roland, Wernli, M., Kolb, H. J., Schlegel, F., Schlag, R., de Wit, M., Trümper, L., Hebart, H., Hahn, M., Thomalla, J., Scheid, C., Schafhausen, P., Verbeek, W., Neubauer, A., Eckart, M. J., Gassmann, W., Pezzutto, A., Schenk, M., Brossart, P., Geer, T., Bildat, S., Schäfer, E., Hochhaus, A., Hasford, J., Hossfeld, D. K., SAKK and the German CML Study Group, Nerl, C., Gratwohl, A.

Publikováno v: Leukemia : normal and malignant hemopoiesis 31, 2398-2406 (2017). doi:10.1038/leu.2017.253
Hehlmann, R; Lauseker, M; Saußele, S; Pfirrmann, M; Krause, S; Kolb, H J; Neubauer, A; Hossfeld, D K; Nerl, C; Gratwohl, A; Baerlocher, Gabriela M.; Heim, D; Brümmendorf, T H; Fabarius, A; Haferlach, C; Schlegelberger, B; Müller, M C; Jeromin, S; Proetel, U; Kohlbrenner, K; ... (2017). Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia, 31(11), pp. 2398-2406. Nature Publishing Group 10.1038/leu.2017.253
Leukemia

Chronic myeloid leukemia (CML)-study IV was designed to explore whether treatment with imatinib (IM) at 400 mg/day (n=400) could be optimized by doubling the dose (n=420), adding interferon (IFN) (n=430) or cytarabine (n=158) or using IM after IFN-fa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3844707224f159ade6c99ad4303c41b
http://edoc.mdc-berlin.de/16712/1/16712oa.pdf